Ziccum, a spin out from Inhalation Sciences, has announced that it submitted a patent application for a temperature-stable dry powder formulation of adenovirus. According to the company, the formulation, which would be suitable for delivery by inhalation, can be held at over 40 °C for more than a week with no degradation.
Ziccum CEO Göran Conradson commented, “This solves a problem no one has been able to solve before. We can formulate vaccines that are safe and stable to transport, without needing costly refrigeration equipment during the last, crucial step in reaching the people in most need.”
Read the Ziccum press release.
